Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Hemoglobin|June 8, 2010
Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapyAnnita Kolnagou, George J KontoghiorghesFrontiers in Bioscience (Landmark Edition)|September 21, 2017
Chelation protocols for the elimination and prevention of iron overload in thalassaemiaAnnita Kolnagou, George John KontoghiorghesCurrent Medicinal Chemistry|November 25, 2005
Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelatorsGeorge J Kontoghiorghes, Annita KolnagouHemoglobin|June 27, 2006
Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral ChelatorsAnnita Kolnagou, George J KontoghiorghesHaematologica|June 21, 2006
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugsGeorge J Kontoghiorghes, Annita KolnagouHemoglobin|May 24, 2011
Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapyAnnita Kolnagou, Marios Kleanthous, George J KontoghiorghesEuropean Journal of Haematology|July 29, 2010
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapyAnnita Kolnagou, Marios Kleanthous, George J KontoghiorghesFrontiers in Bioscience (Elite Edition)|September 22, 2022
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable DiseaseAnnita Kolnagou, Marios Kleanthous, George J KontoghiorghesHemoglobin|June 8, 2010
Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorptionGeorge J Kontoghiorghes, Aspasia Spyrou, Annita KolnagouDrug Safety|June 27, 2003
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamineGeorge J Kontoghiorghes, Katia Neocleous, Annita KolnagouPageof 4